Using autophagy to treat Alzheimer's disease
Modulation of autophagic flux as a therapeutic strategy for Alzheimer's disease
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11212208
This study is looking at how boosting a natural recycling process in our cells might help treat Alzheimer's disease, and it's for people with Alzheimer's who are hoping for new ways to slow down the progression of their condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11212208 on ClinicalTrials.gov |
What this research studies
This research investigates how enhancing a cellular recycling process called autophagy can help treat Alzheimer's disease (AD). The study focuses on small-molecule activators that can restore the normal functioning of autophagy and lysosomes, which are often impaired in AD. By testing these activators in both laboratory models and living organisms, the researchers aim to determine their effectiveness in preventing neuronal damage and alleviating symptoms of Alzheimer's. Patients may benefit from new therapeutic options that could slow disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it due to age or genetic factors.
Not a fit: Patients with other forms of dementia or neurodegenerative diseases unrelated to autophagic dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly slow the progression of Alzheimer's disease and improve patients' quality of life.
How similar studies have performed: Previous research has shown promise in using autophagy modulation as a therapeutic strategy for neurodegenerative diseases, indicating potential for success in this approach.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GOWRISHANKAR, SWETHA — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: GOWRISHANKAR, SWETHA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.